Medical News

RSS

Inhibiting miR-193a decreases tumor growth in SCC

Squamous cell carcinoma (SCC) is a common type of skin cancer. In this paper, Leif Ellisen and colleagues at Mass General Hospital investigated the p53-related proteins p63 and p73 in SCC cells, and discovered a feedback loop between p63, microRNAs (miRs), and p73. In a model of SCC, they found that inhibiting one of these miRs decreased tumor growth and made the cells more sensitive to chemotherapy, highlighting a new potential therapeutic target.

11 Jan 2011

Skin cells for repairing cartilage injury

In this paper, Noriyuki Tsumaki and his team at the Osaka University Graduate School of Medicine, used fibroblasts isolated from adult mouse skin, and expressed proteins used to induce pluripotency along with a factor that promotes a chondrocyte fate.

11 Jan 2011

Teenagers who consume excess sugar may face risk of developing heart disease

Teenagers who consume a lot of added sugars in soft drinks and foods may have poor cholesterol profiles — which may possibly lead to heart disease in adulthood, according to first-of-its-kind research reported in Circulation: Journal of the American Heart Association.

11 Jan 2011

Takeda, Zinfandel enter global licensing agreement for TOMM40 biomarker assay for Alzheimer's disease

Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease.

11 Jan 2011

Breathing tobacco smoke increases blood pressure of pre-school children

If you smoke around your children, they could have high blood pressure or be headed in an unhealthy direction before learning their ABC's, according to research reported in Circulation: Journal of the American Heart Association.

11 Jan 2011

American Red Cross releases Haiti relief and recovery report

The American Red Cross released a one-year report on how the Red Cross has helped hundreds of thousands of Haitian survivors after the January 2010 earthquake, what has been done to respond to new issues such as the cholera outbreak, and plans for the years ahead to support Haiti's recovery.

11 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

Novel scoring system identifies PTEN genetic mutation

Researchers have discovered a method for more precise identification of individuals who should undergo testing for genetic mutations of the tumor suppressor gene PTEN, which associates with a variety of conditions including several types of cancers. The research has created a diagnostic scoring system that improves on established criteria.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers at Nationwide Children's Hospital report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia.

11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

New study finds nitric oxide gas has no therapeutic value in most premature babies

A new Johns Hopkins Children's Center study challenges the widespread practice of treating premature babies with nitric oxide gas to prevent lung problems, neurological damage and death.

11 Jan 2011

Bristol-Myers Squibb, OPKO Health collaborate in relation to new diagnostic test technology

OPKO Health, Inc. today announced that it has entered into a collaboration agreement with Bristol-Myers Squibb Company relating to OPKO's new diagnostic test technology. OPKO's simple blood tests are being developed, based on its proprietary platform technology, to identify biomarkers for a wide variety of diseases including neurodegenerative disorders and various malignancies.

11 Jan 2011

Biologics receives National Comprehensive Cancer Network recognition

Biologics, Inc., an oncology management company, has been recognized by the National Comprehensive Cancer Network® (NCCN®) for its commitment to supporting patient access to quality oncology care. For the first time, the NCCN, a not-for-profit alliance of 21 of the world's leading cancer centers, is recognizing commercial payor and non-payor organizations, including Biologics, which support the appropriate, effective, and efficient use of oncology treatment and care of patients through its new NCCN Recognition Program.

11 Jan 2011

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

LSTM leads six year, £6 million international research consortium on rebuilding of health systems

LSTM is leading a six year, £6 million international research consortium to strengthen knowledge of how health systems which have been damaged in conflict situations are most effectively rebuilt.

11 Jan 2011

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

11 Jan 2011

Aid groups, U.N., U.S. discuss response to Haiti's earthquake as year anniversary approaches

On Friday, the Office of the U.N. Special Envoy to Haiti said that 63.6 percent of the aid international donors "pledged to Haiti in 2010 after a devastating earthquake nearly one year ago" has been disbursed, Deutsche Presse-Agentur/M&C reports (1/7).

11 Jan 2011

MSU researcher believes pregnancy unmasks predispositions to cardiovascular disease

As the rate of preterm delivery rises - accounting for 12.5 percent of all U.S. births - a Michigan State University epidemiologist is using a $3.7 million federal grant to uncover why some mothers who deliver babies early are at an increased risk of developing cardiovascular disease.

11 Jan 2011

Medical News

Inhibiting miR-193a decreases tumor growth in SCC

Skin cells for repairing cartilage injury

Teenagers who consume excess sugar may face risk of developing heart disease

Takeda, Zinfandel enter global licensing agreement for TOMM40 biomarker assay for Alzheimer's disease

Breathing tobacco smoke increases blood pressure of pre-school children

American Red Cross releases Haiti relief and recovery report

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Novel scoring system identifies PTEN genetic mutation

QIAGEN to acquire minority stake in Alacris Theranostics

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

New study finds nitric oxide gas has no therapeutic value in most premature babies

Bristol-Myers Squibb, OPKO Health collaborate in relation to new diagnostic test technology

Biologics receives National Comprehensive Cancer Network recognition

Silicon microdevices may provide new way to screen metastatic breast cancer cells

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

LSTM leads six year, £6 million international research consortium on rebuilding of health systems

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Aid groups, U.N., U.S. discuss response to Haiti's earthquake as year anniversary approaches

MSU researcher believes pregnancy unmasks predispositions to cardiovascular disease

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News